Login to Your Account

Roche Snags Anadys for $230M Amid Changing HCV Landscape

By Jennifer Boggs

Tuesday, October 18, 2011
Anadys Pharmaceuticals Inc., which had been seeking a partner for its hepatitis C virus (HCV) candidate setrobuvir (ANA598), found an acquirer instead, with Roche AG plunking down about $230 million in cash in a deal that analysts say could signal a wave of consolidation in the HCV space as drugmakers race to develop the first all-oral, interferon-free treatment regimen.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription